RA
LYRA

Rosalind Advisors’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Rosalind Advisors’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20,695
Closed -$286K – 37
2024
Q2 		$286K Sell
20,695
-2,195
-10% -$248K 0.22% 36
2024
Q1 		$7.12M Sell
22,890
-14,884
-39% -$3.97M 6.65% 2
2023
Q4 		$9.9M Buy
+37,774
New +$6.84M 8.15% 1

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rosalind Advisors's LYRA Position: Q3 2024 in Review

Rosalind Advisors sold out of LYRA THERAPEUTICS INC (LYRA) in Q3 2024, closing a stake of 20,695 shares — an estimated $286K sold.

Rosalind Advisors first reported a position in LYRA in Q4 2023 and held it in 3 quarters. The position peaked at $9.9M in Q4 2023. 62 funds tracked by Wall St. Rank hold LYRA as of Q3 2024.

  • Rosalind Advisors reported no remaining LYRA THERAPEUTICS INC position as of Q3 2024 after selling out during the quarter.
  • Rosalind Advisors sold 20,695 LYRA THERAPEUTICS INC shares in Q3 2024, an estimated $286K.
  • Rosalind Advisors first reported a position in LYRA THERAPEUTICS INC in Q4 2023 and held it in 3 quarters.
  • Rosalind Advisors's LYRA THERAPEUTICS INC position peaked at $9.9M in Q4 2023.
  • 62 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q3 2024.

Based on Rosalind Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.